ArticleWorld journal of oncology2021

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab).

Rossella De Luca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.